/PROGEN.ST
PROGEN.ST Stock - Prostatype Genomics AB (publ)
Healthcare|Medical - Diagnostics & ResearchSTO
$0.35+3.24%
+$0.01 (+3.24%) • Dec 23
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.39
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PROGEN.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.35 – $0.35
TARGET (TP)$0.40
STOP LOSS$0.32
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.12
52W High$12.20
52W Low$0.32
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $199,000 | $1.36M | $683,000 | $10,000 | $683,878 |
| Gross Profit | $1.92M | $3.73M | $683,000 | $2.51M | $-14,204,212 |
| Gross Margin | 963.8% | 274.9% | 100.0% | 25096.4% | -2077.0% |
| Operating Income | $-40,853,000 | $-39,247,000 | $-28,689,000 | $-15,548,265 | $-16,618,444 |
| Net Income | $-41,051,000 | $-41,435,000 | $-29,087,000 | $-15,629,758 | $-17,408,222 |
| Net Margin | -20628.6% | -3055.7% | -4258.7% | -156297.6% | -2545.5% |
| EPS | $-13.67 | $-12.04 | $-12.59 | $-10.64 | $-25.16 |
Company Overview
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PROGEN.STBeat Rate
100%
Last 1 quarters
Avg Surprise
+20.0%
EPS vs Estimate
Beats / Misses
1/0
Last 12 quarters
Latest EPS
$-0.08
Q3 2023
EPS Surprise History
Q4 21
No data
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
+20.0%
$-0.08vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Feb 12, 2025 | — | — | — | — |
Q2 2024 | May 31, 2024 | — | — | — | — |
Q1 2024 | Feb 15, 2024 | — | — | — | — |
Q4 2023 | Nov 10, 2023 | $-0.06 | — | — | — |
Q3 2023 | Aug 17, 2023 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q2 2023 | May 31, 2023 | — | $-0.19 | — | — |
Q1 2023 | Feb 16, 2023 | — | $-3.60 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-4.24 | — | — |
Q3 2022 | Aug 18, 2022 | — | $-4.93 | — | — |
Q2 2022 | May 12, 2022 | — | $-3.54 | — | — |
Q1 2022 | Feb 24, 2022 | — | $-2.49 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-3.67 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.73 | — | — |
Q2 2021 | May 27, 2021 | — | — | — | — |
Q1 2021 | Mar 31, 2021 | — | $-2.50 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-90.58 | — | — |
Latest News
Loading news...
Frequently Asked Questions about PROGEN.ST
What is PROGEN.ST's current stock price?
Prostatype Genomics AB (publ) (PROGEN.ST) is currently trading at $0.35 per share. The stock has moved +3.24% today.
What is the analyst price target for PROGEN.ST?
No analyst price targets are currently available for this stock.
What sector is Prostatype Genomics AB (publ) in?
Prostatype Genomics AB (publ) operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the STO exchange.
What is PROGEN.ST's market cap?
Prostatype Genomics AB (publ) has a market capitalization of $0.01 billion, making it a small-cap company.
Does PROGEN.ST pay dividends?
No, Prostatype Genomics AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector2CUREX.ST
2cureX AB (publ)
$0.75
Mkt Cap: $0.0B
AINO.ST
Aino Health AB (publ)
$0.18
Mkt Cap: $0.0B
APTA.ST
Aptahem AB (publ)
$1.12
Mkt Cap: $0.0B
CMH.ST
Chordate Medical Holding AB (publ)
$0.61
Mkt Cap: $0.0B
EPIS-B.ST
Episurf Medical AB (publ)
$0.03
Mkt Cap: $0.0B
FLUI.ST
Fluicell AB (publ)
$11.30
Mkt Cap: $0.0B
ODI.ST
ODI Pharma AB
$3.22
Mkt Cap: $0.1B
QLIFE.ST
Qlife Holding AB (publ)
$2.40
Mkt Cap: $0.0B
SPERM.ST
Spermosens AB
$0.01
Mkt Cap: $0.0B
STABL.ST
Stayble Therapeutics AB (publ)
$0.21
Mkt Cap: $0.0B
Explore stocks similar to PROGEN.ST for comparison